Comparing Pulsed Electromagnetic Field Therapy and Pneumatic Compression for Preventing Blood Clots in ICU Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of Pulsed Electromagnetic Field Therapy (PEMF) compared to conventional pneumatic compression for preventing venous thromboembolism (VTE) in patients admitted to the intensive care unit (ICU). It is a prospective, randomized, open-label study involving patients who are at risk for VTE and cannot receive pharmacological prophylaxis. Participants will be enrolled from two hospitals in Belo Horizonte, Brazil, and will be monitored using standardized clinical evaluations and data collection methods. The study will assess the outcomes of both interventions to determine which is more effective in preventing VTE.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients \> 18 years old in ICU
2. PADUA score\> 4 (medical patients) and/or Caprini score\> 3 (surgical patients)
3. Contraindication to pharmacological prophylaxis or indication to combined (pharmacological and mechanical VTE prophylaxis)

Exclusion Criteria:

1. Patients \< 18 years old in ICU
2. Unable to use mechanical prophylaxis due to trauma, burns, fracture, or problems in inferior members that prevent the use of mechanical prophylaxis
3. Life expectations less than 24 hours

Where it's running

• Hospital Vera Cruz, Belo Horizonte, MG, Brazil
  Belo Horizonte, Bh, Brazil Recruiting

Study contacts

• Study coordinator: Eduardo Fonseca Sad, MD
• Email: edu.sad@uol.com.br
• Phone: +55 31 991717860

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma

  In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.

  Recruiting Phase 4 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07907211

• DoACs vs LMWH for blood flow after knee replacement

  This study tests whether rivaroxaban, apixaban, or LMWH work differently to support blood flow in the legs after total knee replacement in adults.

  Recruiting Military Hospital of Tunis · Tunis, Tunis Governorate · NCT07869615

• TRiP-cast score test in adults with acute lower-limb injuries requiring immobilization

  This study tests whether the TRiP(cast) score can predict risk of blood clots in adults with acute lower-limb injuries treated as outpatients.

  Recruiting University of Monastir · Monastir · NCT07863115

• Pulmonary Embolism Registry from Emergency Care to Long-Term Follow-Up

  This registry follows adults with acute pulmonary embolism to see how care is given in the real world and what happens over time.

  Recruiting at 16 sites Azienda Ospedaliero-Universitaria Careggi · Bagno a Ripoli, Tuscany and 15 other locations · NCT07855679

• Prognostic value of the 2026 AHA/ACC PE classification in ED patients with acute PE

  This study tests whether the 2026 AHA/ACC five-category PE classification helps predict 30-day major adverse pulmonary embolism events in adults with acute PE presenting to the ED.

  Recruiting Marmara University Pendik Training and Research Hospital · Istanbul · NCT07805616

• YKYY033 Injection safety and tolerability in adults

  This study tests whether a single dose of YKYY033 injection is safe and tolerable in healthy adults aged 18–55.

  Recruiting Phase 1 Youcare Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality · NCT07786779

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.